Home NDC 57520-1038 Neuro
Product NDC 57520-1038
11-digit product format 575201038
Labeler code 57520
Product ID 57520-1038_89a1b938-32b0-481d-87f4-36e0f1272234
Type HUMAN OTC DRUG
Nonproprietary name Hydrastis canadensis, Taraxacum officinale, Acetylcholine chloride, Adrenalinum, Gaba, Histaminum hydrochloricum, Norepinephrine, Tyramine,
Dosage form LIQUID
Route ORAL
Labeler Apotheca Company
Marketing category UNAPPROVED HOMEOPATHIC
Marketing start 2012-01-16
Marketing end 2022-12-30
Substance .GAMMA.-AMINOBUTYRIC ACID; ACETYLCHOLINE CHLORIDE; EPINEPHRINE; GOLDENSEAL; HISTAMINE DIHYDROCHLORIDE; NOREPINEPHRINE; TARAXACUM OFFICINALE; TYRAMINE
Active strength 6 [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL
Pharmacologic classes Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Catecholamine [EPC], Catecholamine [EPC], Catecholamines [CS], Catecholamines [CS], Cholinergic Agonists [MoA], Cholinergic Receptor Agonist [EPC], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]
NDC exclude flag No
Listing certified through 0000-00-00
Current FDA listing Historical FDA.report record Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 38 matching rows.
View current auxiliary records. · View the auxiliary file history.
Captured / source date, Dataset, Scope table Captured / source date Dataset Scope Package NDC Code Status Snapshot Source SHA-256 2025-12-14 17:58 UTC · source 2025-12-05 excluded product product D Discontinued by firm d630ba8d3edf…732f749b63fb…2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 57520-1038-1 D Discontinued by firm d630ba8d3edf…732f749b63fb…2025-08-27 00:01 UTC · source 2025-08-26 excluded product product D Discontinued by firm f5e01cc5f278…a2eaf40c39c3…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 57520-1038-1 D Discontinued by firm f5e01cc5f278…a2eaf40c39c3…2025-04-01 02:39 UTC · source 2025-03-31 excluded product product D Discontinued by firm 2ef7874e63bc…57b86245f4fa…2025-04-01 02:39 UTC · source 2025-03-31 excluded package package 57520-1038-1 D Discontinued by firm 2ef7874e63bc…57b86245f4fa…2025-03-28 20:22 UTC · source 2025-03-28 excluded product product D Discontinued by firm a1b67e2a42f9…c4cf2c586c0d…2025-03-28 20:22 UTC · source 2025-03-28 excluded package package 57520-1038-1 D Discontinued by firm a1b67e2a42f9…c4cf2c586c0d…2025-03-22 03:12 UTC · source 2025-03-21 excluded product product D Discontinued by firm cfe11265f3b6…090c488252e2…2025-03-22 03:12 UTC · source 2025-03-21 excluded package package 57520-1038-1 D Discontinued by firm cfe11265f3b6…090c488252e2…2025-03-10 12:48 UTC · source 2025-03-10 excluded product product D Discontinued by firm cdf11ea48f46…ba0047e9e063…2025-03-10 12:48 UTC · source 2025-03-10 excluded package package 57520-1038-1 D Discontinued by firm cdf11ea48f46…ba0047e9e063…2025-02-02 03:52 UTC · source 2025-01-31 excluded product product D Discontinued by firm 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded package package 57520-1038-1 D Discontinued by firm 302b2466d912…e7b80fea0513…2025-01-20 13:05 UTC · source 2025-01-20 excluded product product D Discontinued by firm ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded package package 57520-1038-1 D Discontinued by firm ed331223b511…672a5bd82f5f…2025-01-11 03:41 UTC · source 2025-01-10 excluded product product D Discontinued by firm 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded package package 57520-1038-1 D Discontinued by firm 0efc9e666f02…f202fb6c5f17…2024-11-09 02:27 UTC · source 2024-11-08 excluded product product D Discontinued by firm ad56d346431e…cc804d4bbf1e…2024-11-09 02:27 UTC · source 2024-11-08 excluded package package 57520-1038-1 D Discontinued by firm ad56d346431e…cc804d4bbf1e…2024-10-04 04:10 UTC · source 2024-10-03 excluded product product D Discontinued by firm 367a005e9d99…383a685ebd0f…2024-10-04 04:10 UTC · source 2024-10-03 excluded package package 57520-1038-1 D Discontinued by firm 367a005e9d99…383a685ebd0f…2024-07-10 04:00 UTC · source 2024-07-09 excluded product product D Discontinued by firm 557ba5c1ecfa…9c80585c8c6e…2024-07-10 04:00 UTC · source 2024-07-09 excluded package package 57520-1038-1 D Discontinued by firm 557ba5c1ecfa…9c80585c8c6e…2022-08-30 03:57 UTC · source 2022-08-29 excluded product product I Inactivated by FDA fb8cb913e6d1…eb8c232b6be0…2022-08-30 03:57 UTC · source 2022-08-29 excluded package package 57520-1038-1 I Inactivated by FDA fb8cb913e6d1…eb8c232b6be0…2022-04-09 23:13 UTC · source 2022-04-08 excluded product product I Inactivated by FDA 86f5da6cb304…a595104c45d7…2022-04-09 23:13 UTC · source 2022-04-08 excluded package package 57520-1038-1 I Inactivated by FDA 86f5da6cb304…a595104c45d7…2022-04-04 05:40 UTC · source 2022-04-01 excluded product product I Inactivated by FDA bd6a592717d7…303034d00443…2022-04-04 05:40 UTC · source 2022-04-01 excluded package package 57520-1038-1 I Inactivated by FDA bd6a592717d7…303034d00443…2021-12-27 23:28 UTC · source 2021-12-27 excluded product product I Inactivated by FDA 8dfbde2a14a4…c9ff85d89658…2021-12-27 23:28 UTC · source 2021-12-27 excluded package package 57520-1038-1 I Inactivated by FDA 8dfbde2a14a4…c9ff85d89658…2020-12-18 03:04 UTC · source 2020-12-17 excluded product product I Inactivated by FDA e2bbac7714bc…27bdfed8d636…2020-12-18 03:04 UTC · source 2020-12-17 excluded package package 57520-1038-1 I Inactivated by FDA e2bbac7714bc…27bdfed8d636…2020-06-10 20:45 UTC · source 2020-06-10 excluded product product I Inactivated by FDA 9bebd1f3094a…5416666fcb17…2020-06-10 20:45 UTC · source 2020-06-10 excluded package package 57520-1038-1 I Inactivated by FDA 9bebd1f3094a…5416666fcb17…2019-12-08 06:16 UTC · source 2019-12-05 excluded product product E Excluded after deficient or non-compliant submission was not corrected 110d247fa046…a55b01930146…2019-12-08 06:16 UTC · source 2019-12-05 excluded package package 57520-1038-1 E Excluded after deficient or non-compliant submission was not corrected 110d247fa046…a55b01930146…
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
FDA-Initiated Inactive NDC Indexing# DailyMed Socrata Ingredients# Ingredient, Type, UNII table Ingredient Type UNII DailyMed label SPL version Uploaded .GAMMA.-AMINOBUTYRIC ACID ACTIVE INGREDIENT 2ACZ6IPC6I NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 ACETYLCHOLINE CHLORIDE ACTIVE INGREDIENT AF73293C2R NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 EPINEPHRINE ACTIVE INGREDIENT YKH834O4BH NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 GOLDENSEAL ACTIVE INGREDIENT ZW3Z11D0JV NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 HISTAMINE DIHYDROCHLORIDE ACTIVE INGREDIENT 3POA0Q644U NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 NOREPINEPHRINE ACTIVE INGREDIENT X4W3ENH1CV NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 TARAXACUM OFFICINALE ACTIVE INGREDIENT 39981FM375 NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 TYRAMINE ACTIVE INGREDIENT X8ZC7V0OX3 NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 .GAMMA.-AMINOBUTYRIC ACID ACTIVE MOIETY 2ACZ6IPC6I NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 ACETYLCHOLINE ACTIVE MOIETY N9YNS0M02X NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 EPINEPHRINE ACTIVE MOIETY YKH834O4BH NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 GOLDENSEAL ACTIVE MOIETY ZW3Z11D0JV NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 HISTAMINE ACTIVE MOIETY 820484N8I3 NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 NOREPINEPHRINE ACTIVE MOIETY X4W3ENH1CV NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 TARAXACUM OFFICINALE ACTIVE MOIETY 39981FM375 NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 TYRAMINE ACTIVE MOIETY X8ZC7V0OX3 NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 ALCOHOL INACTIVE INGREDIENT 3K9958V90M NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2 WATER INACTIVE INGREDIENT 059QF0KO0R NEURO II (HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACETYLCHOLINE CHLORIDE, ADRENALINUM, GABA, HISTAMINUM HYDROCHLORICUM, NOREPINEPHRINE, TYRAMINE,) LIQUID [APOTHECA COMPANY] 2
Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Marketing end Sample Exclude flag Status 57520-1038-1 57520103801 30 mL in 1 BOTTLE, DROPPER (57520-1038-1) 30 ml 2012-01-16 2022-12-30 No No Current